{"id":"endocrine-therapy-abemaciclib","safety":{"commonSideEffects":[{"rate":"40–50","effect":"Neutropenia"},{"rate":"80–90","effect":"Diarrhea"},{"rate":"30–40","effect":"Fatigue"},{"rate":"25–35","effect":"Nausea"},{"rate":"20–30","effect":"Abdominal pain"},{"rate":"10–20","effect":"Infection"},{"rate":"15–25","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endocrine therapy (such as aromatase inhibitors, tamoxifen, or fulvestrant) suppresses estrogen production or blocks estrogen receptor signaling in hormone receptor-positive breast cancer. Abemaciclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are critical for G1/S cell-cycle transition. The combination overcomes endocrine resistance by simultaneously targeting hormone signaling and cell-cycle checkpoints.","oneSentence":"Endocrine therapy combined with abemaciclib (a CDK4/6 inhibitor) blocks estrogen signaling and cell-cycle progression to inhibit hormone receptor-positive breast cancer growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:23.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)"}]},"trialDetails":[{"nctId":"NCT07490509","phase":"PHASE4","title":"Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2026-04","conditions":"Abemaciclib, Abemaciclib-related Diarrhea, Breast Cancer","enrollment":235},{"nctId":"NCT07487129","phase":"PHASE4","title":"Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-08-25","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT06650423","phase":"","title":"Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-01-05","conditions":"Early Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":319},{"nctId":"NCT07428018","phase":"PHASE2","title":"Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-04-30","conditions":"Breast Cancer, HER2 + Breast Cancer, HR Positive","enrollment":150},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":"Breast Neoplasms","enrollment":3250},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT07407439","phase":"","title":"Real-world Studies of CDK4/6 Inhibitors","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-01","conditions":"Breast Cancer","enrollment":245},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT04923542","phase":"PHASE1, PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":"Brain Metastases, HR+ Metastatic Breast Cancer","enrollment":31},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":"Breast Neoplasms","enrollment":198},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT05501704","phase":"PHASE2","title":"ETHAN - ET for Male BC","status":"RECRUITING","sponsor":"Jose Pablo Leone","startDate":"2023-10-11","conditions":"Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT07214532","phase":"NA","title":"Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Natera, Inc.","startDate":"2026-03","conditions":"Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)","enrollment":725},{"nctId":"NCT07243002","phase":"","title":"Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT04565054","phase":"PHASE3","title":"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2020-09-02","conditions":"Breast Cancer Female","enrollment":1260},{"nctId":"NCT07180056","phase":"","title":"Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Wenjin Yin","startDate":"2025-08-28","conditions":"Breast Cancer","enrollment":229},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT04681768","phase":"","title":"Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2020-12-22","conditions":"Breast Cancer/ Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT03939897","phase":"PHASE1","title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04305834","phase":"PHASE2","title":"Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-03-25","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":43},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT07151911","phase":"","title":"Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2024-08-26","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07130643","phase":"PHASE2","title":"Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xinhong Wu, PhD","startDate":"2024-12-20","conditions":"HR+/HER2- Breast Cancer","enrollment":40},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT04752332","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2021-05-10","conditions":"Breast Neoplasms","enrollment":111},{"nctId":"NCT04975308","phase":"PHASE3","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-10-04","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":874},{"nctId":"NCT06570031","phase":"PHASE1","title":"ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-09","conditions":"Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":46},{"nctId":"NCT03099174","phase":"PHASE1","title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-04","conditions":"Neoplasms, Breast Neoplasms","enrollment":133},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT03675893","phase":"PHASE2","title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-12-24","conditions":"Endometrial Cancer, Ovarian Cancer","enrollment":180},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT04985058","phase":"","title":"Real-world Data in Patients With Breast Cancer Treated With Abemaciclib","status":"RECRUITING","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2021-10-06","conditions":"Breast Cancer","enrollment":108},{"nctId":"NCT05759949","phase":"PHASE1","title":"First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors","status":"COMPLETED","sponsor":"Relay Therapeutics, Inc.","startDate":"2023-03-29","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":41},{"nctId":"NCT05362760","phase":"PHASE4","title":"Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2022-04-27","conditions":"Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT06207734","phase":"PHASE2","title":"Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2024-01-17","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT03155997","phase":"PHASE3","title":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2017-07-12","conditions":"Breast Cancer","enrollment":5637},{"nctId":"NCT06810492","phase":"NA","title":"The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment","status":"NOT_YET_RECRUITING","sponsor":"Hongmei Zheng, PhD","startDate":"2025-04-01","conditions":"Breast Cancer Stage III, Breast Cancer Stage II","enrollment":40},{"nctId":"NCT06805812","phase":"","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-05-01","conditions":"Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic","enrollment":3500},{"nctId":"NCT06344780","phase":"","title":"Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-05-20","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT06621459","phase":"","title":"Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-09-26","conditions":"Brest Cancer, Abemaciclib, Adjuvant Therapy","enrollment":30},{"nctId":"NCT06126003","phase":"","title":"Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.","status":"TERMINATED","sponsor":"BioCorteX Inc","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT06341621","phase":"PHASE3","title":"Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-02","conditions":"Breast Cancer","enrollment":1900},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT04305236","phase":"PHASE2","title":"Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-07-23","conditions":"Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma","enrollment":1},{"nctId":"NCT05789771","phase":"","title":"Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.","status":"COMPLETED","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2022-04-01","conditions":"HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease","enrollment":136},{"nctId":"NCT05766410","phase":"PHASE2","title":"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-09-16","conditions":"Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy","enrollment":60},{"nctId":"NCT04316169","phase":"PHASE1","title":"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2021-10-21","conditions":"Solid Tumor, Advanced Breast Cancer","enrollment":""},{"nctId":"NCT05345860","phase":"NA","title":"Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-03-24","conditions":"Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT02308020","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-04-20","conditions":"Breast Cancer, Non-small Cell Lung Cancer, Melanoma","enrollment":162},{"nctId":"NCT02102490","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06-10","conditions":"Metastatic Breast Cancer","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":486,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Endocrine therapy + Abemaciclib","genericName":"Endocrine therapy + Abemaciclib","companyName":"Japanese Foundation for Cancer Research","companyId":"japanese-foundation-for-cancer-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endocrine therapy combined with abemaciclib (a CDK4/6 inhibitor) blocks estrogen signaling and cell-cycle progression to inhibit hormone receptor-positive breast cancer growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}